FIELD: biotechnology; biomedicine.
SUBSTANCE: present invention relates to the field of biotechnology and biomedicine, in particular to antibodies and their antigen-binding fragments capable of binding to protein CD38, to an isolated nucleic acid molecule encoding an antibody to CD38, and an expression vector containing the above-mentioned nucleic acid; to a host cell for the production of an antibody to CD38 or its antigen-binding fragments, to a method for the production of an antibody to CD38 or its antigen-binding fragment, and to a pharmaceutical composition for the treatment of tumors. In addition, a method for the prevention or treatment of tumors, and a method for the inhibition of protein CD38 binding to ligand CD38 are proposed.
EFFECT: antibody or its antigen-binding fragment, according to the present invention, can destroy CD38+ cells by antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and/or apoptosis.
33 cl, 3 tbl, 11 ex, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY | 2012 |
|
RU2715642C2 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
